Thermo Fisher Completes Brahms Buy | GenomeWeb

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has completed its $471 million acquisition of German diagnostics firm Brahms, the firm said today.

Thermo Fisher initially announced the deal in early September. The acquisition will complement its immunoassay test portfolio and expand its reagent manufacturing capabilities in Europe.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.